GSK's Malaria Vaccine To Be Piloted In Sub-Saharan Africa
This article was originally published in SRA
Executive Summary
GlaxoSmithKline's malaria vaccine, Mosquirix (RTS,S), is to be administered to young children in a limited number of African countries as part of a pilot scheme that could lead to wider deployment of the vaccine in three to five years, provided its safety and efficacy are shown to be acceptable.